ABVC BioPharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for ABVC BioPharma and similar public comparables like Local Bounti, Steakholder Foods, Moolec Science, Above Food and more.

ABVC BioPharma Overview

About ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.


Founded

2015

HQ

United States

Employees

19

Financials (FY)

Revenue: -
EBITDA: ($7M)

EV

$40M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

ABVC BioPharma Financials

ABVC BioPharma reported last fiscal year revenue of - and negative EBITDA of ($7M).

In the same fiscal year, ABVC BioPharma generated - in gross profit, ($7M) in EBITDA losses, and had net loss of ($8M).

Revenue (LTM)


ABVC BioPharma P&L

In the most recent fiscal year, ABVC BioPharma reported revenue of - and EBITDA of ($7M).

ABVC BioPharma is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.

See analyst estimates for ABVC BioPharma
Last FY202320242025202620272028
Revenue-$152K$510K-
Gross Profit-($150K)$509K-
Gross Margin-(98%)100%-
EBITDA($7M)($8M)($4M)($7M)
EBITDA Margin-(5335%)(852%)-
EBIT Margin-(5390%)(923%)-
Net Profit($8M)($11M)($5M)($8M)
Net Margin-(6899%)(962%)-
Net Debt$873K---

Financial data powered by Morningstar, Inc.

ABVC BioPharma Stock Performance

ABVC BioPharma has current market cap of $38M, and enterprise value of $40M.

Market Cap Evolution


ABVC BioPharma's stock price is $1.46.

ABVC BioPharma share price decreased by 7.6% in the last 30 days, and by 30.0% in the last year.

ABVC BioPharma has an EPS (earnings per share) of $-0.30.

See more trading valuation data for ABVC BioPharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$40M$38M-27.4%-7.6%41.7%-30.0%$-0.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

ABVC BioPharma Valuation Multiples

ABVC BioPharma trades at (5.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for ABVC BioPharma

EV / Revenue (LTM)


ABVC BioPharma Financial Valuation Multiples

As of July 10, 2026, ABVC BioPharma has market cap of $38M and EV of $40M.

ABVC BioPharma has a P/E ratio of (4.8x).

Last FY202320242025202620272028
EV/Revenue-n/m79.5x-
EV/EBITDA(5.4x)(5.0x)(9.3x)(5.4x)
EV/EBIT(5.7x)(4.9x)(8.6x)(5.7x)
EV/Gross Profit-n/m79.6x-
P/E(4.8x)(3.6x)(7.7x)(4.8x)
EV/FCF(13.6x)(9.5x)(22.4x)(13.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified ABVC BioPharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

ABVC BioPharma Margins & Growth Rates

See estimated margins and future growth rates for ABVC BioPharma

ABVC BioPharma Margins

2024202720282029
Gross Margin100%
EBITDA Margin(852%)
EBIT Margin(923%)
Net Margin(962%)
FCF Margin(355%)

ABVC BioPharma Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth234%(100%)
Gross Profit Growth(440%)(100%)
EBITDA Growth(47%)71%
EBIT Growth(43%)52%
Net Profit Growth(53%)61%
FCF Growth(58%)65%

Data powered by FactSet, Inc. and Morningstar, Inc.

ABVC BioPharma Operational KPIs

ABVC BioPharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

Access forward-looking KPIs for ABVC BioPharma
Last FY20232024202620272028
Revenue per Employee$0.0M--
Opex per Employee$0.4M--
G&A Expenses to Revenue-4595%988%
R&D Expenses to Revenue-697%35%
Opex to Revenue-5292%1023%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

ABVC BioPharma Competitors

ABVC BioPharma competitors include Local Bounti, Steakholder Foods, Moolec Science, Above Food, Next Meats Holdings, Planethic Group, Modern Plant Based Foods, Jyong Biotech, Oatly and Beyond Meat.

Most ABVC BioPharma public comparables operate across Plant-Based Food.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Local Bounti10.5x10.5x(13.0x)-
Steakholder Foods--(0.7x)-
Moolec Science0.2x-(0.6x)-
Above Food0.4x-(3.6x)-
Next Meats Holdings3.2x-(0.9x)-
Planethic Group1.0x-(4.6x)-
Modern Plant Based Foods5.5x-(5.0x)-
Jyong Biotech--(92.0x)-

This data is available for Pro users. Sign up to see all ABVC BioPharma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About ABVC BioPharma

When was ABVC BioPharma founded?ABVC BioPharma was founded in 2015.
Where is ABVC BioPharma headquartered?ABVC BioPharma is headquartered in United States.
How many employees does ABVC BioPharma have?As of today, ABVC BioPharma has over 19 employees.
Who is the CEO of ABVC BioPharma?ABVC BioPharma's CEO is Uttam Yashwant Patil.
Is ABVC BioPharma publicly listed?Yes, ABVC BioPharma is a public company listed on Nasdaq.
What is the stock symbol of ABVC BioPharma?ABVC BioPharma trades under ABVC ticker.
When did ABVC BioPharma go public?ABVC BioPharma went public in 2004.
Who are competitors of ABVC BioPharma?ABVC BioPharma main competitors include Local Bounti, Steakholder Foods, Moolec Science, Above Food, Next Meats Holdings, Planethic Group, Modern Plant Based Foods, Jyong Biotech, Oatly, Beyond Meat.
What is the current market cap of ABVC BioPharma?ABVC BioPharma's current market cap is $38M.
Is ABVC BioPharma profitable?No, ABVC BioPharma is not profitable.
How many companies ABVC BioPharma has acquired to date?ABVC BioPharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies ABVC BioPharma has invested to date?ABVC BioPharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to ABVC BioPharma

Lists including ABVC BioPharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial